Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive OncologyCompany Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro BiosciencesPredictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States
Predictive Oncology Closes Registered Direct OfferingPITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (
NASDAQPOAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (
NASDAQPOAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced that it has entered into definitive agreements for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 19, 2025, subject to the satisfaction of customary closing conditions.
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug RepurposingCompany successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LBRDA, NARI, ML, POAI on Behalf of ShareholdersNEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RHE, FUBO, POAI on Behalf of ShareholdersNEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Renovaro Issues Shareholder Letter and Provides Corporate UpdateCompany to Host International Roadshow the Week of January 13, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Predictive Oncology Inc. (Nasdaq - POAI), SunLink Health Systems, Inc. (NYSE American - SSY), Universal Stainless & Alloy Products, Inc. (Nasdaq - USAP), PattersonBALA CYNWYD, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (
NASDAQPOAI) to Renovaro Inc. is fair to Predictive shareholders.
Renovaro to Acquire Predictive Oncology in All-Stock TransactionAcquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data
Predictive Oncology Announces Agreement to be Acquired by Renovaro- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic AlternativesPITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (
NASDAQPOAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024.
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic UpdateCompany initiates process to explore a broad range of strategic alternatives to maximize shareholder value
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferencePredictive Oncology (
NASDAQPOAI) is announcing participation at the upcoming H.C. Wainwright 26th Annual Global Investment Conference to be held September 9-11 in New York. The company is scheduled to deliver a virtual presentation, which will be available on-demand starting Monday, September 9 at 7 a.m. ET. The Predictive Oncology management team will also host one-on-one meetings during the conference.
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (
NASDAQPOAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY.
TinyGemsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reports on Study Confirming Long-Term Stability, Viability of Proprietary Tumor Specimen BiobankPredictive Oncology (
NASDAQPOAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is reporting on a study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples available within its proprietary biobank. According to the report, the study validates highly reproducible drug response data as well as enabling and supporting the AI platform to model and predict patient outcomes on historical samples. The company has released a new white paper that discusses this study, and the importance of tumor sample viability, in greater detail.
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2024 Financial Results, Provides Business UpdatePredictive Oncology (
NASDAQPOAI) today announced its financial and operating results for the second quarter ended June 30, 2024, and provided a corporate update. The company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. In addition, it concluded Q2 2024 with $5.3 million of cash and cash equivalents, compared to $8.7 million as of December 31, 2023, and $4.1 million in stockholders’ equity as of June 30, 2024, compared to $8.3 million as of December 31, 2023.
BioMedNewsBreaks — Predictive Oncology Inc. (NASDAQ: POAI) Announces Expansion of Live-Cell Tumor Platform ApplicationsPredictive Oncology (
NASDAQPOAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target validation; the platform also offers a proprietary tool that accounts for patient heterogeneity and increases Probability of Technical Success. In addition, Predictive Oncology released a new white paper that discusses these capabilities in greater detail.
Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline DevelopmentFindings demonstrate real-world applications of Company’s AI platform to support biomarker discovery, clinical trial optimization and target validation
